Recent News

• 11.13.2025 - NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
• 10.19.2025 - European Society for Medical Oncology (ESMO) Congress
• 10.19.2025 - European Society for Medical Oncology (ESMO) Congress
• 10.18.2025 - NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
• 10.14.2025 - NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy
• 09.05.2025 - NuCana Compliant with All Nasdaq Continued Listing Criteria
• 09.05.2025 - NuCana Compliant with All Nasdaq Continued Listing Criteria
• 09.05.2025 - NuCana Compliant with All Nasdaq Continued Listing Criteria
• 09.03.2025 - NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025
• 09.03.2025 - NuCana to Present Data on NUC-7738’s Synergy with PD-1 Inhibitors at the ESMO Congress 2025

Recent Filings

• 11.05.2025 - EX-99.1 EX-99.1
• 11.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.20.2025 - EX-99.1 EX-99.1
• 10.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 10.14.2025 - EX-99.1 EX-99.1
• 10.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.05.2025 - EX-99.1 EX-99.1
• 09.05.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.03.2025 - EX-99.1 EX-99.1